Form D · Biotechnology

Voyager Therapeutics, Inc.

Lexington, MA · CIK 0001640266

Offering snapshot reported Jan 17, 2024 · SEC filing

Reported sold
$20M
Offering amount: $20M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 3, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 17, 2024Initial$19,999,999No comparison1SEC filing
Mar 3, 2023Initial$39,032,821No comparison1SEC filing
Apr 23, 2015Initial$60,000,003No comparison10SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$400K
Finders' fees
$0
Form D file number
021-502725

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Chestnut Partners, Inc.38387

Source: Form D, filed Jan 17, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Mitchell S. Bloom Executive
Todd Carter Executive
Grace Colon Director
Jacquelyn Fahey Sandell Executive
James A. Geraghty Director
Robert W. Hesslein Executive
Michael Higgins Director
Steven Hyman Director
Mark Levin Director
Catherine Mackey Director
Jude Onyia Director
Steven Paul Director, Executive
Peter Pfreundschuh Executive
Glenn Pierce Director
Alfred Sandrock Director, Executive
George Scangos Director
Robin Swartz Executive
Nancy Vitale Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
75 Hayden Avenue
Lexington, MA, 02421